title: Gastroparesis and the current use of prokinetic drugs.
abstract: Gastroparesis is a chronic gastric motility disorder in which there is delayed gastric emptying of solids plus or minus liquids. Symptoms of gastroparesis may range from early satiety and nausea in mild cases to chronic vomiting, dehydration, and nutritional compromise in severe cases. Diagnosis of gastroparesis is based on demonstration of delayed gastric emptying of a radiolabeled solid meal in the absence of mechanical obstruction. A number of gastrointestinal and systemic disorders may impair gastric motility with resultant gastroparesis. Approximately one third of patients with gastroparesis have no identifiable underlying cause (so called idiopathic gastroparesis). Management of gastroparesis involves four areas: (1) nutritional support, (2) antiemetic drugs, (3) prokinetic drugs, and (4) surgical therapy (in a very small subset of patients). Gastroparesis is often a chronic, relapsing condition; 80% of patients require maintenance antiemetic and prokinetic therapy and 20% require long-term nutritional supplementation. In the near future, the most promising advances in the treatment of patients with gastroparesis will most likely come from the area of combination pharmacological therapy. In the long term, developments in the area of intestinal pacing and intestinal transplantation may offer further treatment options in this difficult disorder.
authors.affiliation: Division of Gastroenterology, University of Virginia, Charlottesville 22908.
authors.forename: B J
authors.initials: BJ
authors.lastname: Kendall
authors.forename: R W
authors.initials: RW
authors.lastname: McCallum
mesh_terms: D020117:Cisapride; D004294:Domperidone / Q000627:therapeutic use; D005746:Gastric Emptying; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D013272:Stomach Diseases / Q000188:drug therapy*
chemical_list: D010880:Piperidines; D004294:Domperidone; D008787:Metoclopramide; D020117:Cisapride